Legend Strategy International Holdings Group Co., Ltd. AI Stock Analysis
Want to see HK:1355 full AI Analyst Report?
Legend Strategy International Holdings Group Co., Ltd. (1355) AI Stock Analysis
Legend Strategy International Holdings Group Co., Ltd.
(HKEX:1355)
The score is primarily constrained by severe financial deterioration, negative equity, losses, and cash burn. Strong price momentum provides meaningful support, but overbought indicators and loss-based valuation limit the overall score.
Legend Strategy International Holdings Group Co., Ltd. (1355) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 634.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.46M
- Price to Earnings (P/E)
- -46.8
- Beta (1Y)
- -0.07
- Revenue Growth
- 8.34%
- EPS Growth
- 80.94%
- Country
- Hong Kong
- Employees
- 94
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Travel Lodging
Legend Strategy International Holdings Group Co., Ltd. Business Overview & Revenue Model
Company Description
Biosysen Limited, an investment holding company, engages in the accommodation operation and consultancy business in the People's Republic of China. It also provides property facilities management, franchise co-operation management, accommodation outs...
Legend Strategy International Holdings Group Co., Ltd. Financial Statement Overview
Summary
Financial health is severely weakened by negative equity, substantial net losses, collapsing margins, negative operating cash flow, and deeply negative free cash flow. The underlying statement scores average 18.3/100, mapped to 48/99.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.95M | 51.30M | 40.68M | 67.66M | 63.00M | 70.56M |
| Gross Profit | -1.44M | 1.11M | 21.67M | 45.35M | 6.88M | 15.63M |
| EBITDA | -23.00M | -20.66M | 25.66M | -23.72M | 21.91M | 38.05M |
| Net Income | -8.90M | -43.53M | -21.12M | -38.18M | -7.79M | 4.98M |
Balance Sheet | ||||||
| Total Assets | 71.51M | 80.44M | 75.05M | 127.32M | 196.17M | 240.18M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 2.44M | 13.86M | 4.26M | 6.35M | 17.05M |
| Total Debt | 101.91M | 162.19M | 164.99M | 181.60M | 175.86M | 203.62M |
| Total Liabilities | 124.37M | 183.34M | 180.40M | 210.06M | 217.04M | 242.16M |
| Stockholders Equity | -14.39M | -35.25M | -42.35M | -36.35M | 2.18M | 12.32M |
Cash Flow | ||||||
| Free Cash Flow | -11.50M | -49.60M | 24.01M | 34.51M | 6.41M | 14.06M |
| Operating Cash Flow | -4.72M | -32.69M | 24.27M | 35.16M | 9.35M | 30.40M |
| Investing Cash Flow | -29.05M | -29.64M | -250.00K | -644.00K | -2.93M | -16.31M |
| Financing Cash Flow | 22.89M | 50.81M | -11.98M | -34.94M | -19.01M | -19.81M |
Legend Strategy International Holdings Group Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1355, the sentiment is Positive. The current price of 0.66 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.24, and above the 200-day MA of 0.16, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 79.86 is Negative, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1355.
Legend Strategy International Holdings Group Co., Ltd. Peers Comparison
Overall Rating
HK:018475Outperform
HK:122172Outperform
HK:020169Neutral- HK:135552Neutral
HK:061748.5Neutral
HK:007845Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0184 | 75Outperform | HKD 762.05M | 2.52 | 8.45% | 5.58% | 6.80% | 67.22% |
| HK:1221 | 72Outperform | HKD 1.62B | 16.44 | 2.28% | 2.22% | 3.53% | -7.42% |
| HK:0201 | 69Neutral | HKD 653.13M | 17.38 | 0.90% | ― | 6.29% | ― |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| HK:1355 | 52Neutral | HKD 1.24B | -46.78 | 35.86% | ― | 8.34% | 80.94% |
| HK:0617 | 49Neutral | HKD 200.63M | -0.24 | -10.26% | ― | 63.78% | 49.79% |
| HK:0078 | 45Neutral | HKD 341.54M | -0.65 | -6.04% | ― | 49.29% | 79.61% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1355 | Legend Strategy International Holdings Group Co., Ltd. | 0.66 | 0.53 | 436.89% | |
| HK:0184 | Keck Seng Investments (Hong Kong) | 2.24 | 0.18 | 8.47% | |
| HK:0201 | Magnificent Hotel Investments Limited | 0.07 | 0.00 | 4.29% | |
| HK:1221 | Sino Hotels (Holdings) Ltd. | 1.35 | -0.12 | -8.23% | |
| HK:0617 | Paliburg Holdings Limited | 0.18 | -0.12 | -39.33% | |
| HK:0078 | Regal Hotels International Holdings Limited | 0.35 | -0.24 | -40.68% |
Legend Strategy International Holdings Group Co., Ltd. Corporate Events
Biosysen Sets Dilution Protections on HK$50 Million Convertible Bonds
Biosysen Limited, formerly known as Legend Strategy International Holdings Group Co., Ltd., is a Cayman Islands–incorporated company listed in Hong Kong that uses convertible bonds as part of its financing strategy. Its HK$50 million bond issue can b...
Biosysen Raises HK$39 Million Through Fully Placed Rights Issue to Fund R&D
Biosysen Limited, formerly Legend Strategy International Holdings Group Co., Ltd., is a Hong Kong-listed company incorporated in the Cayman Islands and currently emphasizing research and development initiatives. The firm plans to deploy new capital m...
Biosysen Limited Publishes Unaudited Interim Results for First Half of 2026
Biosysen Limited has released its unaudited condensed consolidated interim results for the six months ended 30 June 2026, prepared in line with Hong Kong Stock Exchange listing rules. The interim report, reviewed by the board’s audit committee, has b...
Biosysen Rights Issue Undersubscribed; Unplaced Shares to Be Marketed via Compensatory Placing
Biosysen Limited has reported the results of its rights issue, launched on the basis of one rights share for every two existing shares at a subscription price of HK$0.068 per share. The offer comprised 596,532,580 rights shares, all available to qual...
Biosysen forecasts swing to profit on lease-termination gain
Biosysen Limited has issued a positive profit alert indicating that it expects to swing to a net profit of about HK$20 million for the six months ended 30 June 2026, compared with a loss of approximately HK$13.5 million a year earlier. The improvemen...
Biosysen Sets Board Meeting to Review Interim Results and Potential Dividend
Biosysen Limited has scheduled a board meeting for 31 August 2026 to review and approve the unaudited interim results of the company and its subsidiaries for the six months ended 30 June 2026. The meeting will also consider a possible recommendation...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026